Responses
Other responses
Jump to comment:
- Published on: 27 July 2016
- Published on: 27 July 2016
- Published on: 27 July 2016Re:DPP4is are safeShow More
Dear Editor,
Andrea Giaccari asserts that I wrote in my editorial that sitagliptin in the TECOS trial "caused" 20% increase in the secondary outcome of congestive heart failure. That is not what I wrote. I wrote that "the study data remain consistent with" a 20% increase in this adverse outcome. While the wide confidence interval is also consistent with a reduction in heart failure risk, the primary goal of the TECOS tr...
Conflict of Interest:
None declared. - Published on: 27 July 2016DPP4is are safeShow More
Dear Editor,
I read with interest the comments of Dr. Fenton. In his editorial (Evid Based Med. 2016 Jun;21(3):81-2) Dr Fenton stated that sitagliptin caused in TECOS "a 20% increase in the secondary outcome of congestive heart failure (intention-to-treat HR 1.00, 95% CI 0.82 to 1.20, p=0.98)". This is really misleading. With exactly the same numbers Dr. Fenton could state that sitagliptin caused an 18% reduction in hos...
Conflict of Interest:
None declared.